Treatment Sequencing Strategies in R/R Multiple Myeloma

A panel of experts on multiple myeloma introduce themselves and discuss recent CAR T-cell therapy approvals in earlier treatment lines for patients with relapsed/refractory disease.

The panel discusses recent updates on bispecific antibodies for patients with relapsed/refractory multiple myeloma, highlighting studies investigating talquetamab, teclistamab, and elranatamab.

Myeloma specialists discuss clinical trials investigating CAR T-cell therapies in patients with relapsed/refractory disease.

Surbhi Sidana, MD, provides clinical insights on treatment sequencing strategies for patients with relapsed/refractory multiple myeloma.

Binod Dhakal, MD, presents the case of a 66-year-old patient with IgG kappa multiple myeloma, and the panel discusses treatment considerations and decisions.

The panel discusses the utilization of CAR T-cell therapy for patients with multiple myeloma, highlighting treatment selection, sequencing, and insurance considerations.

Adriana Rossi, MD, presents the case of a 60-year-old patient with stage III kappa light chain multiple myeloma, and members of the panel provide their initial impressions.

Continuing discussion centered on a patient case, the panel discusses bispecific antibody combinations and the role of BCMA-targeting CAR T-cell therapies in relapsed/refractory multiple myeloma.

The panel concludes the discussion by offering future perspectives on the evolving treatment landscape in multiple myeloma, highlighting exciting developments and ongoing research.